151,486 Shares in CVS Health Corporation $CVS Bought by United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund

Key Points

• United Super Pty Ltd disclosed a new fourth-quarter stake in CVS Health, buying 151,486 shares worth about $12.0 million. Institutional ownership of CVS remains high at 80.66%.
• CVS reported strong recent results, with Q1 EPS of $2.57 beating expectations and revenue of $100.43 billion topping estimates. The company also raised/confirmed guidance for FY 2026 EPS of $7.30 to $7.50.
• The stock has been boosted by positive operational news, including CVS Caremark restoring coverage of Zepbound, Aetna launching mental-health access tools, and CVS expanding its AI partnership with Salesforce. Analysts remain constructive, with an average Moderate Buy rating and a target price near $98.88.

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund bought a new stake in CVS Health Corporation (NYSE:CVS - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 151,486 shares of the pharmacy operator's stock, valued at approximately $12,022,000.

Other large investors have also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd raised its position in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after purchasing an additional 281 shares during the last quarter. Ares Financial Consulting LLC bought a new position in CVS Health in the fourth quarter valued at about $29,000. Dogwood Wealth Management LLC raised its position in CVS Health by 93.7% in the fourth quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator's stock valued at $29,000 after purchasing an additional 179 shares during the last quarter. GoalVest Advisory LLC bought a new position in CVS Health in the fourth quarter valued at about $32,000. Finally, MidAtlantic Capital Management Inc. bought a new position in CVS Health in the fourth quarter valued at about $35,000. 80.66% of the stock is currently owned by institutional investors.

Insider Activity at CVS Health

In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the transaction, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 3,441,551 shares of company stock worth $323,703,977. Corporate insiders own 0.85% of the company's stock.

CVS Health Trading Up 1.0%

NYSE CVS opened at $92.95 on Friday. The business has a 50 day simple moving average of $81.71 and a 200 day simple moving average of $79.47. CVS Health Corporation has a one year low of $58.50 and a one year high of $98.43. The stock has a market capitalization of $118.59 billion, a P/E ratio of 40.95, a P/E/G ratio of 0.90 and a beta of 0.60. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66.

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion during the quarter, compared to analysts' expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm's revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Research analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were issued a $0.665 dividend. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 2.9%. CVS Health's dividend payout ratio is presently 117.18%.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Caremark said it will restore coverage of Eli Lilly’s weight-loss drug Zepbound and add Lilly’s new obesity pill to its standard drug plans, a move that could improve member access and make CVS’s drug formularies more competitive. Article Title
• Positive Sentiment: CVS Health Ventures led a $40 million investment in H1, reinforcing CVS’s push into health-tech and AI-driven provider data accuracy, which could support long-term digital growth initiatives. Article Title
• Positive Sentiment: Aetna launched “Aetna Mental Health On Demand,” giving members faster access to mental-health care and adding another visible example of CVS expanding its integrated care offerings. Article Title
• Positive Sentiment: CVS also expanded its Salesforce partnership to improve call-center service with AI tools, which may lower friction for members and providers and improve operating efficiency. Article Title
• Neutral Sentiment: Several reports focused on CVS’s dividend safety, with commentary suggesting the payout remains covered by cash flow; this is reassuring for income investors, but it is not a direct catalyst. Article Title
• Negative Sentiment: CVS filed suit to challenge Tennessee’s new PBM-pharmacy breakup law, signaling regulatory and legal pressure on part of its business model; however, this is more of a risk factor than an immediate earnings driver. Article Title

Wall Street Analysts Forecast Growth

Several research firms have commented on CVS. UBS Group increased their target price on CVS Health from $97.00 to $100.00 and gave the company a "buy" rating in a research report on Thursday, May 7th. TD Cowen upped their price target on CVS Health from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Monday, May 11th. Piper Sandler reduced their price target on CVS Health from $101.00 to $99.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 31st. Sanford C. Bernstein upped their price target on CVS Health from $94.00 to $106.00 and gave the company an "outperform" rating in a research report on Tuesday, May 12th. Finally, The Goldman Sachs Group upped their price target on CVS Health from $95.00 to $97.00 and gave the company a "buy" rating in a research report on Thursday, February 12th. Twenty-two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $98.88.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.